Alembic Pharmaceuticals Limited
National Stock Exchange of IndiaTotal Valuation
Alembic Pharmaceuticals Limited carries a market capitalization of 164.26B, placing it among publicly traded companies globally. Its enterprise value stands at 204.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 164.26B |
| Enterprise Value | 204.61B |
Valuation Ratios
Alembic Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 33.93.
| PE Ratio | 33.93 |
| PS Ratio | 3.00 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Alembic Pharmaceuticals Limited trades at an EV/EBITDA multiple of 26.59 and an EV/FCF ratio of 282.77. The EV/Sales ratio of 3.00 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.59 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.00 |
| EV / EBITDA | 26.59 |
| EV / EBIT | 26.59 |
| EV / FCF | 282.77 |
Financial Position
Alembic Pharmaceuticals Limited maintains a current ratio of 3.43, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.05, indicating elevated leverage, while an interest coverage ratio of 8.63 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 3.43 |
| Quick Ratio | 0.11 |
| Debt / Equity | 46.05 |
| Debt / EBITDA | N/A |
| Interest Coverage | 8.63 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 77.48 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Alembic Pharmaceuticals Limited has paid 1.39B in income taxes, reflecting an effective tax rate of 18.80.
| Income Tax | 1.39B |
| Effective Tax Rate | 18.80 |
Stock Price Statistics
Alembic Pharmaceuticals Limited's stock has declined approximately -16.62676% over the past 52 weeks. The 50-day moving average sits at 762.29, while the 200-day moving average is 802.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | -16.62676% |
| 50-Day Moving Average | 762.29 |
| 200-Day Moving Average | 802.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Alembic Pharmaceuticals Limited generated 68.21B in revenue and converted that into 6.03B in net income, yielding earnings per share of 30.53. EBITDA reached 7.69B, while operating income came in at 7.69B.
| Revenue | 68.21B |
| Gross Profit | 50.14B |
| Operating Income | 7.69B |
| Pretax Income | 7.40B |
| Net Income | 6.03B |
| EBITDA | 7.69B |
| EBIT | 7.69B |
| Earnings Per Share (EPS) | 30.53 |
Margins
Alembic Pharmaceuticals Limited operates with a gross margin of 73.51, reflecting its pricing power and cost economics. The operating margin of 11.28 and net profit margin of 8.84 provide insight into operational efficiency.
| Gross Margin | 73.51 |
| Operating Margin | 11.28 |
| Pretax Margin | 10.85 |
| Profit Margin | 8.84 |
| EBITDA Margin | 11.28 |
Scores
Alembic Pharmaceuticals Limited posts an Altman Z-Score of 14.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 14.00 |